Cancer Research The Future of Cancer Research: Science and Patient Impact  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 50, 3585-3588, June 15, 1990]
© 1990 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Farzad, Z.
Right arrow Articles by Morton, D. L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Farzad, Z.
Right arrow Articles by Morton, D. L.

Lymphocyte Subset Alterations in Nodes Regional to Human Melanoma1

Zohreh Farzad2, Alistair J. Cochran, William H. McBride, J. Dixon Gray, Victoria Wong and Donald L. Morton

Division of Surgical Oncology [Z. F., A. J. C., D. L. M.], Department of Radiation Oncology [W. H. M.], and Department of Pathology [A. J. C.], University of California, Los Angeles, California 90024, and Department of Rheumatology, University of Southern California, Los Angeles, California 90033 [J. D. G., V. W.]

The lymphocyte subpopulations in tumor-draining lymph nodes of melanoma patients were determined using two-color flow cytometry. Data were analyzed according to: (a) the staging of the melanoma; (b) whether or not the nodes contained tumor; and (c) their distance from the primary tumor.

Compared with Stage I patients (without metastasis), uninvolved nodes of stage II patients (with nodal metastases) had a significant decrease in helper/inducer (CD4+) T-cells (P < 0.001), with a corresponding increase in cytotoxic/suppressor (CD8+) cells (P < 0.001) and Leu 19+ natural killer (CD56+) cells (P < 0.01). In some patients the presence of tumor within a node was associated with a large decrease in CD3+ total T-cells, whereas in others tumor involvement had little influence on lymphocyte phenotypes. When analyzed by distance from the primary tumor, nodes closest to tumor in Stage I patients contained a smaller percentage of CD19+ B-cells. In Stage II, tumor-free nodes nearest to tumor showed an increase in CD19+ cells, but statistical significance was not reached. CD56+ natural killer cells increased progressively in nodes near tumor and were more numerous in Stage II uninvolved nodes compared with Stage I nodes.

Alterations in phenotypically defined lymph node lymphocytes occur in nodes regional to melanoma as the disease progresses, as growth of metastases occurs, and in tumor-free nodes nearest to tumor. These alterations may be essential to the establishment and progression of metastases.

1 Supported by Grant CA 43658 from the NIH.

2 To whom requests for reprints should be addressed, at UCLA-Medical Center, 9th Floor Louis Factor Bldg. 9–267, Los Angeles, CA 90024.

Received 7/31/89. Revised 12/19/89.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1990 by the American Association for Cancer Research.